Substudies 02A, 02B, and 02C: To assess the safety and tolerability of investigational treatment combinations based on the proportion of participants with adverse events (AEs). Substudies 02A and 02B: To evaluate objective response rate (ORR) as assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). Substudy 02C: To evaluate pathological complete response (pCR) rate as assessed by central review of the pathology results.
What is the full name of this clinical trial?
MK-3475-U02-01: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma: Master